COVID-19 Vaccine Developer CureVac Increases 431% in Value After IPO
Business

COVID-19 Vaccine Developer CureVac Increases 431% in Value After IPO

The company has seen its value grow by a whopping 431% since its Initial Public Offering. As a result, CureVac was able to get up to $231 million in initial funding, which is expected to go towards research and development.

Thank you! You have been added
to our daily newsletter.

We just added to our newsletter list.
Keep an eye out for the latest news from cursor in your inbox!

OK, GOT IT